Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10597657rdf:typepubmed:Citationlld:pubmed
pubmed-article:10597657lifeskim:mentionsumls-concept:C0043210lld:lifeskim
pubmed-article:10597657lifeskim:mentionsumls-concept:C0724441lld:lifeskim
pubmed-article:10597657lifeskim:mentionsumls-concept:C0007226lld:lifeskim
pubmed-article:10597657lifeskim:mentionsumls-concept:C0028754lld:lifeskim
pubmed-article:10597657lifeskim:mentionsumls-concept:C0817096lld:lifeskim
pubmed-article:10597657lifeskim:mentionsumls-concept:C0011786lld:lifeskim
pubmed-article:10597657lifeskim:mentionsumls-concept:C0001758lld:lifeskim
pubmed-article:10597657lifeskim:mentionsumls-concept:C0013790lld:lifeskim
pubmed-article:10597657lifeskim:mentionsumls-concept:C0444706lld:lifeskim
pubmed-article:10597657lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:10597657lifeskim:mentionsumls-concept:C0442828lld:lifeskim
pubmed-article:10597657pubmed:issue7lld:pubmed
pubmed-article:10597657pubmed:dateCreated2000-1-24lld:pubmed
pubmed-article:10597657pubmed:abstractTextAn anorectic drug, dexfenfluramine (dF) is commonly used in obesity treatment. The aim of our study was to investigate if dexfenfluramine used alone or together with alpha 2-adrenolitic yohimbine (Y), can change cardiovascular state in obese women.lld:pubmed
pubmed-article:10597657pubmed:languageenglld:pubmed
pubmed-article:10597657pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10597657pubmed:citationSubsetIMlld:pubmed
pubmed-article:10597657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10597657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10597657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10597657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10597657pubmed:statusMEDLINElld:pubmed
pubmed-article:10597657pubmed:issn0006-6648lld:pubmed
pubmed-article:10597657pubmed:authorpubmed-author:NowakAAlld:pubmed
pubmed-article:10597657pubmed:authorpubmed-author:JanuszMMlld:pubmed
pubmed-article:10597657pubmed:authorpubmed-author:HartlebMMlld:pubmed
pubmed-article:10597657pubmed:authorpubmed-author:WalugaMMlld:pubmed
pubmed-article:10597657pubmed:authorpubmed-author:KarpelEElld:pubmed
pubmed-article:10597657pubmed:issnTypePrintlld:pubmed
pubmed-article:10597657pubmed:volume138lld:pubmed
pubmed-article:10597657pubmed:ownerNLMlld:pubmed
pubmed-article:10597657pubmed:authorsCompleteYlld:pubmed
pubmed-article:10597657pubmed:pagination359-63lld:pubmed
pubmed-article:10597657pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:10597657pubmed:meshHeadingpubmed-meshheading:10597657...lld:pubmed
pubmed-article:10597657pubmed:meshHeadingpubmed-meshheading:10597657...lld:pubmed
pubmed-article:10597657pubmed:meshHeadingpubmed-meshheading:10597657...lld:pubmed
pubmed-article:10597657pubmed:meshHeadingpubmed-meshheading:10597657...lld:pubmed
pubmed-article:10597657pubmed:meshHeadingpubmed-meshheading:10597657...lld:pubmed
pubmed-article:10597657pubmed:meshHeadingpubmed-meshheading:10597657...lld:pubmed
pubmed-article:10597657pubmed:meshHeadingpubmed-meshheading:10597657...lld:pubmed
pubmed-article:10597657pubmed:meshHeadingpubmed-meshheading:10597657...lld:pubmed
pubmed-article:10597657pubmed:meshHeadingpubmed-meshheading:10597657...lld:pubmed
pubmed-article:10597657pubmed:meshHeadingpubmed-meshheading:10597657...lld:pubmed
pubmed-article:10597657pubmed:meshHeadingpubmed-meshheading:10597657...lld:pubmed
pubmed-article:10597657pubmed:articleTitleCardiovascular changes after treatment with dexfenfluramine and yohimbine in obese women measured by thoracic electrical bioimpedance.lld:pubmed
pubmed-article:10597657pubmed:affiliationDepartment of Gastroenterology, Silesian Medical Academy, Katowice, Poland.lld:pubmed
pubmed-article:10597657pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10597657pubmed:publicationTypeClinical Triallld:pubmed